# Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W

Source: https://onco.cc/trials/nct07185997/  
OnCo record `nct07185997` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Furmonertinib in non-small-cell lung cancer and small-cell lung cancer, run by ArriVent BioPharma, Inc., now recruiting.

## Summary

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations is a phase 3 interventional study registered as NCT07185997 by ArriVent BioPharma, Inc., with 480 participants planned, started 2025-12-17 and due to reach its primary completion in 2029-02. Interventions recorded: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice. Conditions listed: Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07185997
- Phase: 3
- Setting: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
- Sponsor: ArriVent BioPharma, Inc.
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT07185997: https://clinicaltrials.gov/study/NCT07185997

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/)
- companies: [ArriVent BioPharma](https://onco.cc/companies/arrivent/)

---
JSON: https://onco.cc/api/v1/entities/nct07185997.json